MO020EFFICACY AND SAFETY OF THE LONG-ACTING C5 INHIBITOR RAVULIZUMAB IN PATIENTS WITH POSTPARTUM ATYPICAL HAEMOLYTIC URAEMIC SYNDROME
Sign Up to like & getrecommendations! Published in 2020 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfaa140.mo020
Abstract: Atypical haemolytic uraemic syndrome (aHUS) triggered by pregnancy is a rare and under-recognised disease caused by dysregulation of the alternative complement pathway that occurs in approximately 1 in 25,000 pregnancies. The 311 phase 3 trial… read more here.
Keywords: patients postpartum; inhibitor; ravulizumab; atypical haemolytic ... See more keywords